Serialization in the pharmaceutical industry isn’t just about regulatory compliance—it’s about ensuring patient safety and supply chain integrity. However, achieving compliance can be challenging, as companies often struggle with fragmented systems, data inconsistencies, and the complexity of global regulatory requirements. Many businesses rely on separate serialization solutions that do not integrate with their ERP systems, leading to inefficiencies and gaps in tracking. This is where RxERP changes the game. As the sole provider of a serialized ERP system, RxERP is a trusted partner for pharmaceutical companies seeking an industry-specific, cloud-hosted platform to automate drug serialization and tracking across the supply chain. The platform’s distinctive framework embeds serialization directly into the core ERP system, streamlining compliance, improving visibility, and enabling accurate, real-time data exchange across the supply chain. “Our platform helps ensure adherence to regulations like the Drug Supply Chain Security Act (DSCSA), minimizing risks and maintaining the highest standards for manufacturers, wholesale distributors, and 3PL providers,” says Steve Madsen, CEO of RxERP. This platform additionally features licensure verification, inventory and warehouse management, CRM, and a white-label e-Commerce solution equipped with PCI-compliant checkout capabilities. By consolidating these capabilities into a single system, RxERP eliminates inefficiencies caused by disconnected solutions, allowing pharmaceutical companies to manage end-to-end supply chain operations seamlessly. For pharmaceutical companies, compliance challenges range from product serialization and traceability to maintaining data integrity and regulatory reporting. RxERP addresses these concerns by ensuring that each drug package remains distinctly identifiable throughout its journey, preventing counterfeit products from infiltrating the market. The system safeguards data accuracy regarding product movements, expiration dates, and inventory levels to prevent the distribution of expired medications. It also streamlines regulatory reporting by automatically generating and submitting essential documentation to authorities like the FDA, simplifying an otherwise complex and time consuming process..

The human amniotic membrane is the innermost layer of the placenta that protects the developing fetus, playing a vital role during pregnancy. Research confirms this biologically rich tissue holds remarkable therapeutic potential well beyond gestation. Packed with collagen, antimicrobial peptides, anti-inflammatory cytokines and essential growth factors such as EGF and TGF-β, the membrane actively supports epithelial healing, calms inflammation and delivers measurable improvements in wound care and ocular surface repair. Axolotl Biologix is at the forefront of translating this scientific promise into clinical impact. By developing targeted biologic therapies derived from amniotic tissue, it is redefining how complex wounds and soft tissue injuries are treated. What was once discarded as medical waste is now being transformed into a powerful tool for regenerative healing. Its flagship allografts, Axolotl Graft^™ and Axolotl DualGraft^™, embody this innovative solution. Purpose-built to leverage the natural regenerative properties of the human amniotic membrane, the advanced biologics create a three-dimensional, extracellular matrix that covers and shields the wound, reinforces structural support and delivers key biological cues that accelerate granulation tissue formation and encourage scar-minimizing regeneration. “Our mission is to activate the body’s intrinsic repair mechanisms and improve the likelihood of functional recovery, especially where traditional interventions have failed,” says Josh Sandberg, CEO. Physician insights inform every stage of product development, from the most common wound dimensions to the anatomical barriers that challenge conventional approaches. Feedback drives ongoing refinement, ensuring each outcome aligns with evolving standards of care and addresses real-world wound-healing needs..